找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪(fǎng)問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Lebensqualit?t im Alter; Generationenbeziehun Andreas Motel-Klingebiel (Dr.),Hans-Joachim Kondra Book 2002 Springer Fachmedien Wiesbaden 20

[復(fù)制鏈接]
31#
發(fā)表于 2025-3-26 23:03:00 | 只看該作者
32#
發(fā)表于 2025-3-27 03:23:41 | 只看該作者
r the use in parasitology (He?mánek and Prokopi? 1989). In this study we investigated the possibility of thymic preparations to influence the resistance to model parasite infections (2 helminthoses — cysticercosis and ascaridosis and 2 protozooses — coccidiosis and cryptosporidiosis) in intact and i
33#
發(fā)表于 2025-3-27 07:59:59 | 只看該作者
34#
發(fā)表于 2025-3-27 12:38:34 | 只看該作者
Betina Hollsteintoxic side effects (Schumann and others, 1989). Reduction of toxicity may be accomplished by encapsulation of MTPPE in liposomes, which are taken up preferably by the cells of the MPS. The question is whether liposome-encapsulated MTPPE (LE-MTPPE) retains its activity. LE-MTPPE has proven to be bene
35#
發(fā)表于 2025-3-27 16:16:28 | 只看該作者
Jan Marbachsing nodal regions that may not be irradiated with more conformal techniques. Traditional forms of radiation in particular pose challenges for combination trials with immunotherapy. This chapter explores these issues in more detail and provides insights as to how radiation therapy can be optimized t
36#
發(fā)表于 2025-3-27 18:04:11 | 只看該作者
Frank Lettke auditory complications can lead to speech recognition deficits and sensorineural hearing loss. Ocular toxicities are among the most common adverse events resulting from the use of these agents. The majority of ocular immune-related adverse events (irAEs) are mild, low-grade, non-sight threatening,
37#
發(fā)表于 2025-3-28 01:25:04 | 只看該作者
38#
發(fā)表于 2025-3-28 02:46:10 | 只看該作者
39#
發(fā)表于 2025-3-28 08:14:48 | 只看該作者
Heinz Blaumeiser,Thomas Klie development to predict response to immunotherapy and risk of toxicity. This book chapter is a comprehensive review of immunotherapeutic approaches, both approved and investigational, for the treatment of renal cell carcinoma, urothelial carcinoma, and prostate cancer.
40#
發(fā)表于 2025-3-28 11:37:24 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 21:07
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
孟州市| 大理市| 余庆县| 岚皋县| 小金县| 翁牛特旗| 泰安市| 宕昌县| 延吉市| 赞皇县| 临夏县| 蚌埠市| 苏尼特左旗| 长子县| 龙州县| 罗田县| 抚远县| 孝昌县| 太保市| 阿坝县| 定州市| 库尔勒市| 浑源县| 临颍县| 贵南县| 宁远县| 新河县| 齐河县| 屏边| 安阳市| 通榆县| 遂川县| 叶城县| 临湘市| 陵水| 余姚市| 东阿县| 江口县| 横山县| 亳州市| 泸州市|